WHO Preferred Product Characteristics for Malaria Vaccines: Bridging Vaccine R&D with Public Health
V Moorthy – SAGE, 11 Apr 2013

Excerpt
Updated Vision
Safe and effective vaccines against Plasmodium falciparum and Plasmodium vivax that prevent transmission, disease and death to enable malaria eradication.

Updated Strategic Goals
By 2030, license vaccines targeting Plasmodium falciparum and Plasmodium vivax and encompassing the following two goals, for use by the international public health community:
–       Malaria vaccines with a protective efficacy of at least 70-80 % against clinical malaria, suitable for administration to appropriate at risk groups in malaria-endemic areas.
–       Malaria vaccines that reduce transmission of the parasite and thereby substantially reduce the incidence of human malaria infection. This will enable elimination in multiple settings.